Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

BACKGROUND: We conducted a randomized, phase II, multicenter study to evaluate the anti-epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with chemoradiotherapy (CRT) with standard-dose capecitabine as neoadjuvant treatment for wild-type KRAS locally advanced rectal cancer (LARC). PATIENTS AND METHODS: Patients with wild-type KRAS, T3-4 and/or N+ LARC were randomly assigned to receive CRT with or without P (6 mg/kg). The primary end-point was pathological near-complete or complete tumor response (pNC/CR), defined as grade 3 (pNCR) or 4 (pCR) histological regression by Dworak classification (DC). RESULTS: Forty of 68 patients were randomly assigned to P + CRT and 28 to CRT. pNC/CR was achieved in 21 patients (53%) treated with P + CRT [95% confidence interval (CI) 36%-69%] versus 9 patients (32%) treated with CRT alone (95% CI: 16%-52%). pCR was achieved in 4 (10%) and 5 (18%) patients, and pNCR in 17 (43%) and 4 (14%) patients. In immunohistochemical analysis, most DC 3 cells were not apoptotic. The most common grade ≥3 toxic effects in the P + CRT/CRT arm were diarrhea (10%/6%) and anastomotic leakage (15%/4%). CONCLUSIONS: The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespecified thresholds. The addition of panitumumab increased toxicity.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

BACKGROUND: Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma. PATIENTS AND METHODS: Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i.v. day 1 every 2 weeks until disease progression or unacceptable toxicity. The primary end point was disease stabilisation rate [complete response (CR), partial response (PR) or stable disease (SD)] at week 12 (DSR12); secondary end points were best overall response, PFS, overall survival (OS) and adverse events. RESULTS: Sixty-two patients (median age 59 years) enrolled at nine Swiss centres. DSR12 was 52% (PR: 10 patients and SD: 22 patients). Confirmed overall response rate was 16.1% (CR: 1 patient and PR: 9 patients). Median PFS and OS were 4.2 and 9.6 months. OS (12.0 versus 9.2 months; P = 0.014) was higher in BRAF V600E wild-type patients. CONCLUSIONS: The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF wild-type patients.

HSC(F) 07/2014

DAO (DFP) 01/14 - Audit Of Grants To Local Government Bodies

Seguiment de l'evolució de la recuperació del bosc de ribera en la zona afectada per l'incendi del riu Canaletes del 20/07/2009. Proposta de campanya de voluntariat ambiental en rius per la custòdia i recuperació fluvial

El riu Canaletes va resultar afectat per l’ incendi que es va produir a Horta de Sant Joan el juliol de l’any 2009. El foc va malmetre bona part de la flora i fauna de la zona, però un dels ecosistemes que en va sortir més perjudicat va ser el del bosc de ribera, ecosistema molt fràgil en front de pertorbacions d’aquest tipus, ja que la seva capacitat de regeneració no és tant senzilla ni ràpida com en altres ecosistemes mediterranis com podrien ser els boscos de pi blanc. No obstant, si que existeixen algunes espècies de ribera que presenten una ràpida resposta als incendis com és el cas dels salzes o alguns pollancres o àlbers, que en aquest cas, poc temps després del foc ja presentaven rebrots, segons observacions realitzades al camp. Per comprovar l’evolució de la recuperació del bosc de ribera en la zona afectada per l’incendi, es van realitzar diverses sortides de camp. D’aquestes observacions, es va poder deduir que actualment el bosc de ribera de la zona estudiada, evoluciona segons les previsions realitzades en estudis immediatament posteriors al foc, de manera que hi estan proliferant de manera ràpida bardisses amb esbarzer, gavarrera, roldor i sanguinyol, en aquells llocs que abans de l’incendi eren ocupats per arbres caducifolis.

Student Support Determination 07-08 (PDF 167 KB)

Financial support arrangements in the 2007/08 academic year for Allied Health Professional Students and Medical and Dental students from year five study

SRF Report 2006/07 - Glossary of Terms (PDF 127 KB)

Glossary of Terms to the Strategic Resources Framework Report 2006/07

Safe Parenting Handbook (PDF 1.07 Mb)

This handbook was published in conjunction with the 4 Area Child Protection Committees

National Child Measurement Programme: Detailed Analysis of the 2006/07 National Dataset

The National Child Measurement Programme (NCMP) weighs and measures children in Reception (typically aged 4 - 5 years) and (aged 10 - 11 years) annually. The report highlights the usefulness of the NCMP Dataset in furthering our understanding of underweight, overweight and obesity in children, as well as highlighting some areas where improvements can be made in the programme, or where further analysis and investigation is required. The purpose of this report is not to provide specific local results, but an understanding from national-level analysis that can be used to inform local uses and analysis of NCMP data.

Supporting Healthy Lifestyles: The Natioanl Child Measurement Programme - Guidance for 2006 - 07 school year

The Department of Health is providing a central data store for child obesity data collected by PCTs to be available for live implementation by the end of June 2006. The central data store will be accessible by PCTs via Unify, the DH performance management system.

Tackling health inequalities: 2005-07 policy and data update for the 2010 national target

This document provides an update on progress to meet the health inequalities national target to reduce the gap as measured by infant mortality and life expectancy, by 10% by 2010. It includes an assessment of whether the 70 spearhead area local authorities, which map to 62 PCTs, are on track to meet the life expectancy target.

National Child Measurement Programme. Detailed Analysis of the 2006/07 Dataset

The National Child Measurement Programme (NCMP) weighs and measures children in Reception (typically aged 4 - 5 years) and (aged 10 - years) annually. The report highlights the usefulness of the NCMP Dataset in furthering our understanding of underweight, overweight and obesity in children, as well as highlighting some areas where improvements can be made in the programme, or where further analysis and investigation is required. The purpose of this report is not to provide specific local results, but an understanding from national-level analysis that can be used to inform local uses and analysis of NCMP data.

National Child Measurement Programme: Detailed Analysis of the 2006/07 National Dataset

The National Obesity Observatory has produced a new report - National Child Measurement Programme: Detailed Analysis of the 2006/07 National Dataset. The report highlights the usefulness of the NCMP for advancing our understanding of underweight, overweight and obesity in children. The report looks at the effects of socio-demographic and other factors on the reported prevalence of childhood obesity. It also identifies areas where improvements can be made, and where further analysis and investigation are required.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

PURPOSE: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer. EXPERIMENTAL DESIGN: Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. Treatment consisted of docetaxel (75 mg/m(2) every 3 weeks or 35 mg/m(2) on days 1, 8, 15 every 4 weeks) in combination with cetuximab (400 mg/m(2) on day 1 and then 250 mg/m(2) weekly). The primary endpoint was progression-free survival (PFS) at 12 weeks defined as the absence of prostate-specific antigen (PSA), radiographic, or clinical progression. Evaluation of known biomarkers of response and resistance to cetuximab (EGFR, PTEN, amphiregulin, epiregulin) was conducted. RESULTS: Thirty-eight patients were enrolled at 15 Swiss centers. Median age was 68 years and median PSA was 212 ng/mL. PFS at 12 weeks was 34% [95% confidence interval (CI), 19%-52%], PFS at 24 weeks was 20%, and median overall survival (OS) was 13.3 months (95% CI, 7.3-15.4). Seven patients (20%) had a confirmed ≥ 50% and 11 patients (31%) a confirmed ≥ 30% PSA decline. About 47% of enrolled patients experienced grade 3 and 8% grade 4 toxicities. A significantly improved PFS was found in patients with overexpression of EGFR and persistent activity of PTEN. CONCLUSIONS: EGFR inhibition with cetuximab might improve the outcome of patients with mCRPC. A potential correlation between EGFR overexpression, persistent expression of PTEN, and EGFR inhibition should be investigated further.